Convatec welcomes postponement of Local Coverage Determinations (LCDs) on skin substitutes until January 2026

London, UK, 11 April 2025 – Convatec, a leading medical products and technologies company, welcomes the postponement of the LCDs on skin substitutes in the United States until January 2026. Medicare patients in the US, supported by healthcare professionals (HCPs), will continue to benefit from InnovaMatrix^®.

Convatec welcomes the postponement by the Centers for Medicare & Medicaid Services (CMS) of the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the treatment of Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs). We are grateful to the US Administration, Congress, the Department of Health and Human Services (HHS) and CMS for this decision which means that Medicare patients with DFUs and VLUs will continue to benefit from access to InnovaMatrix^®.

InnovaMatrix^® is an excellent product delivering strong real-world results for patients and is trusted by clinicians. Convatec remains committed to evidence-based medicine to improve outcomes for patients and choice for HCPs. Our randomised controlled trials (RCTs) are on track to report in 2026. This will complement our published real-world evidence (RWE), including RWE published in December 2024.

We believe any future policies for skin substitute products should focus on serving the best interests of patients, protecting patient and provider choice, and delivering value for payors. It is vital that responsible and innovative companies like Convatec can continue to invest in pioneering skin substitute products in the US. Convatec is committed to continuing to work collaboratively with the US Administration and CMS on the development of future policies.

Notes to editors

Convatec’s InnovaMatrix^® is a leading porcine placental-derived extra-cellular matrix for treatment of chronic, surgical and trauma wounds. The product is cleared by the US Food and Drug Administration (FDA) in 15 separate medical indications, based on an established predicate product, under a 510k medical device licence. Patients and HCPs have experienced first-hand the positive, sometimes limb-saving, impact that InnovaMatrix^® products have on chronic wounds. 

The postponement means that Medicare patients in the US will continue to benefit from the clinical effectiveness of InnovaMatrix^® for all 15 FDA-approved indications. 

Contact

Media: MediaRelations@convatec.com 

Investor Relations: ir@convatec.com

About Convatec 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com